Oncotarget

Research Papers:

Prognostic significance of ZEB1 and ZEB2 in digestive cancers: a cohort-based analysis and secondary analysis

Huihui Chen, Wei Lu, Chongjie Huang, Kefeng Ding, Dajing Xia, Yihua Wu and Mao Cai _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:31435-31448. https://doi.org/10.18632/oncotarget.15634

Metrics: PDF 642 views  |   HTML 1428 views  |   ?  


Abstract

Huihui Chen1,*, Wei Lu1,3,*, Chongjie Huang2,*, Kefeng Ding1, Dajing Xia3, Yihua Wu3,4 and Mao Cai2

1Department of Oncology, Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China

2Department of Anorectal Surgery, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China

3Department of Toxicology, Zhejiang University School of Public Health, Hangzhou, China

4Department of Epidemiology and Health Statistics, Zhejiang University School of Public Health, Hangzhou, China

*These authors have considered co-first authors

Correspondence to:

Mao Cai, email: caicai20012001@sina.com

Yihua Wu, email: georgewuer@126.com

Keywords: ZEB family, digestive cancer, prognostic value, cohort-based analysis, secondary analysis

Received: October 02, 2016     Accepted: November 24, 2016     Published: February 23, 2017

ABSTRACT

Background: Digestive cancers are common malignancies worldwide, however there are few effective prognostic markers available. In this study we comprehensively investigated the prognostic significance of ZEB1 and ZEB2 in digestive cancers.

Methods: Electronic databases were searched and studies met the selection criteria were included. Study information was recorded and quality assessment was performed according to the REMARK guideline. Hazard ratios and its corresponding 95% confidence intervals were extracted and pooled. Sensitivity analyses, subgroup analyses, cumulative meta-analyses and secondary analyses were also performed to increase the stability and reliability of our results.

Results: 24 cohort studies were included in the study. High ZEB1 and ZEB2 levels predicted poor overall survival, meanwhile high ZEB2 levels predicted poor disease free survival for digestive cancer patients. From subgroup analyses we observed ZEB1 was found to be significantly associated with poor overall survival for patients with pancreatic cancer, gastric cancer and colorectal cancer, while ZEB2 was found to be significantly associated with poor overall survival for patients with hepatocellular carcinoma and gastric cancer. Furthermore, by conducting secondary analyses we confirmed both ZEB1 and ZEB2 played important roles in gastric cancer prediction. In addition, we found high ZEB1 and ZEB2 expression were significantly associated with depth of invasion, lymph node metastasis and TNM stage in digestive cancer patients.

Conclusions: The present study validated the prognostic value and clinicopathological association of ZEB1 and ZEB2 in digestive cancers, especially in gastric cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15634